Equities Analysts Offer Predictions for NTLA FY2029 Earnings

Intellia Therapeutics, Inc. (NASDAQ:NTLA) – Stock analysts at Brookline Capital Management issued their FY2029 earnings per share (EPS) estimates for Intellia Therapeutics in a research note issued to investors on Monday, January 6th. Brookline Capital Management analyst L. Cann anticipates that the company will post earnings per share of $93.13 for the year. The consensus estimate for Intellia Therapeutics’ current full-year earnings is ($5.12) per share.

Intellia Therapeutics (NASDAQ:NTLA) last issued its earnings results on Thursday, November 7th. The company reported ($1.34) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.37) by $0.03. The business had revenue of $9.10 million for the quarter, compared to the consensus estimate of $8.28 million. During the same quarter in the prior year, the business earned ($1.38) EPS. Intellia Therapeutics’s revenue for the quarter was down 24.1% compared to the same quarter last year.

A number of other equities analysts have also commented on the stock. Chardan Capital increased their price target on shares of Intellia Therapeutics from $88.00 to $91.00 and gave the stock a “buy” rating in a report on Monday, November 18th. The Goldman Sachs Group cut their price objective on shares of Intellia Therapeutics from $31.00 to $20.00 and set a “neutral” rating for the company in a research note on Friday, October 25th. Stifel Nicolaus lowered their price target on shares of Intellia Therapeutics from $80.00 to $64.00 and set a “buy” rating for the company in a report on Wednesday, September 11th. Oppenheimer cut their price target on shares of Intellia Therapeutics from $70.00 to $60.00 and set an “outperform” rating on the stock in a report on Monday, November 11th. Finally, Royal Bank of Canada reaffirmed an “outperform” rating and set a $54.00 price objective on shares of Intellia Therapeutics in a research note on Thursday, September 19th. One research analyst has rated the stock with a sell rating, six have given a hold rating, eleven have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $54.94.

Intellia Therapeutics Stock Performance

NASDAQ:NTLA opened at $12.02 on Wednesday. Intellia Therapeutics has a 52-week low of $11.34 and a 52-week high of $34.87. The stock has a fifty day moving average of $13.96 and a 200 day moving average of $19.20. The firm has a market capitalization of $1.22 billion, a price-to-earnings ratio of -2.21 and a beta of 1.83.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in NTLA. ARK Investment Management LLC raised its holdings in Intellia Therapeutics by 5.7% during the third quarter. ARK Investment Management LLC now owns 12,255,440 shares of the company’s stock valued at $251,849,000 after acquiring an additional 659,651 shares during the period. State Street Corp boosted its position in shares of Intellia Therapeutics by 17.9% during the 3rd quarter. State Street Corp now owns 5,143,534 shares of the company’s stock valued at $105,700,000 after acquiring an additional 780,754 shares during the last quarter. Geode Capital Management LLC increased its position in Intellia Therapeutics by 2.2% in the third quarter. Geode Capital Management LLC now owns 2,343,310 shares of the company’s stock worth $48,164,000 after purchasing an additional 49,367 shares during the last quarter. FMR LLC grew its stake in shares of Intellia Therapeutics by 5.0% in the 3rd quarter. FMR LLC now owns 2,339,522 shares of the company’s stock worth $48,077,000 after buying an additional 111,104 shares in the last quarter. Finally, Federated Hermes Inc. lifted its holdings in shares of Intellia Therapeutics by 19.2% in the 2nd quarter. Federated Hermes Inc. now owns 2,300,889 shares of the company’s stock valued at $51,494,000 after acquiring an additional 371,189 shares during the last quarter. 88.77% of the stock is currently owned by institutional investors.

Insider Activity

In related news, CEO John M. Leonard sold 26,807 shares of Intellia Therapeutics stock in a transaction on Friday, January 3rd. The stock was sold at an average price of $12.18, for a total value of $326,509.26. Following the completion of the sale, the chief executive officer now owns 941,115 shares of the company’s stock, valued at $11,462,780.70. The trade was a 2.77 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Insiders sold 28,735 shares of company stock worth $349,909 over the last three months. 3.20% of the stock is currently owned by corporate insiders.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.